Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis

Cover Page

Abstract


Aim. To evaluate the effectiveness and tolerability of the drug in patients with undifferentiated peripheral inflammatory arthritis (UPIA).

Materials and methods. We observed 60 patients (39 women and 21 men) met G. Hazlewood et al., UPIA criteria, 2011. Patients were divided into 3 groups: with monoarthritis, oligoarthritis and polyarthritis. They took aceclofenac 100 mg twice day for 3 weeks.

Results. We noted significant decreasing in pain level according to visual analogue scale: in patients with monoarthritis – by 69.3 mm (p<0.001); in oligoarthritis group – by 47.5 mm (p<0.001), in patients with polyarthritis – by 30 mm (p<0.001). The life quality by the EQ-5D-5L index was improved too in all groups from 0.616 to 0.829 (p<0.001). The satisfaction with the therapy was: in monoarthritis patients (80% of patients and 93% of doctors noted good results), in oligoarthritis group (53% and 39% accordingly) and polyarthritis (74% and 64% respectively). We suppose the difference was due to the fact that mono- and oligoarthritis patients suffered from initial forms of seronegative spondylarthropathy, in which the effectiveness of NSAIDs is traditionally higher; polyarthritis patients probably had debut of rheumatoid arthritis. Adverse events of therapy were mild. We noted gastrointestinal tract symptoms (dyspepsia) and increased ALT in 10 patients and increased blood pressure – in 1 patient. The symptoms did not require discontinuation of therapy.

Сonclusion. Post-registration observational study of first Russian generic aceclofenac (“Alental”, Vertex, Russia) was conducted. In UPIA patients aceclofenac therapy was most effective in mono- and oligoarthritis patients. The first Russian generic aceclofenac (“Alental”, Vertex, Russia) has good efficacy, tolerability and safety and can be recommended for arthritis treatment.


Full Text

Restricted Access

About the authors

B. V. Zavodovsky

Zborovsky Research Institute of Clinical and Experimental Rheumatology

Author for correspondence.
Email: seeword@mail.ru
ORCID iD: 0000-0002-8864-9570

Russian Federation, Volgograd

д.м.н., проф., зав. лаб. методов лечения и профилактики заболеваний суставов

L. E. Sivordova

Zborovsky Research Institute of Clinical and Experimental Rheumatology

Email: seeword@mail.ru
ORCID iD: 0000-0002-0965-6060
Scopus Author ID: 367822
ResearcherId: Е-4103-2016

Russian Federation, Volgograd

к.м.н., в.н.с. лаб. методов лечения и профилактики заболеваний суставов

Yu. V. Polyakova

Zborovsky Research Institute of Clinical and Experimental Rheumatology

Email: seeword@mail.ru
ORCID iD: 0000-0002-3022-4166
Scopus Author ID: 57193421928
ResearcherId: J-6669-2017

Russian Federation, Volgograd

к.м.н., с.н.с. лаб. методов лечения и профилактики заболеваний суставов

Yu. R. Akhverdyan

Zborovsky Research Institute of Clinical and Experimental Rheumatology

Email: seeword@mail.ru
ORCID iD: 0000-0001-8010-6777

Russian Federation, Volgograd

к.м.н., с.н.с. лаб. методов лечения и профилактики заболеваний суставов

E. V. Papichev

Zborovsky Research Institute of Clinical and Experimental Rheumatology

Email: seeword@mail.ru
ResearcherId: Е-4103-2016

Russian Federation, Volgograd

м.н.с. лаб. методов лечения и профилактики заболеваний суставов

References

  1. Hazlewood G, Aletaha D, Carmona L, et al. Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. J Rheumatol. 2011;38(Suppl. 87). doi: 10.3899/jrheum.101076
  2. Нехайчик Т.А., Рудой А.С., Бова А.А. Современные аспекты диагностики, тактика ведения пациентов с недифференцированным артритом. Евразийский журнал внутренней медицины. Рекомендации и мнения экспертов. 2014;1:24-8 [Nekhaychik TA, Rudoi AS, Bova AA. Modern aspects of diagnosis, management tactics for patients with undifferentiated arthritis. Evrazijskij zhurnal vnutrennej mediciny. Rekomendacii i mnenija jekspertov. = Eurasian Journal of Internal Medicine. Recommendations and expert opinions. 2014;1:24-8 (In Russ.)]. https://euat.ru/magazine/number-1-year-2014-book-0/sovremennye-aspekty-diagnostiki-taktika-vedenija-pacientov-s-nedifferencirovannym-artritom.
  3. Лучихина Е.Л., Каратеев Д.Е., Новиков A.A. и др. Прогнозирование развития ревматоидного артрита у больных с ранним недифференцированным артритом. Научно-практическая ревматология. 2009;2:31-7 [Luchikhina EL, Karateev DE, Novikov AA, et al. Prediction of the development of rheumatoid arthritis in patients with early undifferentiated arthritis. Rheumatology Science and Practice. 2009;2:31-7 (In Russ.)]. https://cyberleninka.ru/article/n/prognozirovanie-razvitiya-revmatoidnogo-artrita-u-bolnyh-s-rannim-nedifferentsirovannym-artritom.
  4. Каратеев Д.Е., Лучихина Е.Л., Тогизбаев Г. Современные принципы ведения больных ранним артритом. РМЖ. 2008;24:1610. Ссылка активна на 25.02.2020 [Karateev DE, Luchikhina EL, Togizbaev G. Modern principles of management of patients with early arthritis. Russkij medicinskij zhurnal = Russian medical journal. 2008;24:1610 (In Russ.)]. https://www.rmj.ru/articles/revmatologiya/Sovremennye_principy_vedeniya_bolynyh__rannim_artritom/#ixzz67W7cGz7m
  5. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, Dijkmans BA. One year outcome of undifferentiated polyarthritis. Ann Rheum Dis. 2002;61(8):700-3. doi: 10.1136/ard.61.8.700
  6. Quinn MA, Green MJ, Marzo-Ortega H. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum. 2003;48(11):3039-45. https://www.ncbi.nlm.nih.gov/pubmed/14613264. doi: 10.1002/art.11269
  7. Bizzaro N, Bartoloni E, Morozzi G, et al. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther. 2013;15:16. doi: 10.1186/ar4148
  8. Александрова Г.А., Поликарпов А.В., Голубев Н.А. и др. Заболеваемость взрослого населения России в 2018 году с диагнозом, установленным впервые в жизни. Статистические материалы. Ч. III. М.: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава Российской Федерации, ФГБУ «ЦНИИОИЗ» Минздрава России, 2017. Ссылка активна на 20.02.2020 [Alexandrova GA, Polikarpov AV, Golubev NA, et al. The incidence of adult population in Russia in 2018 with a diagnosis established for the first time in life. Statistical materials. Part III. Moscow: Department monitoring, analysis and strategic development of the Health Ministry of the Russian Federation, the FSBU «CNIIOIS» of the Russian Ministry of Health, 2017 (In Russ.)]. https://mednet.ru/images/materials/statistika/zabolevaemost_2019.ZIP
  9. Насонов Е.Л. Рекомендации EULAR по диагностике и лечению раннего артрита: 2016. Научно-практическая ревматология. 2017;55(2):138-50 [Nasonov EL. The 2016 EULAR guidelines for the diagnosis and treatment of early arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):138-50 (In Russ.)]. doi: 10.14412/1995-4484-2017-138-150
  10. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017. pii: annrheumdis-2016-210715. doi: 10.1136/annrheumdis-2016-210715
  11. Verschueren P, de Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid ridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74:27-34. doi: 10.1136/annrheumdis-2014-205489
  12. Den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy (“COBRA-light”) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. 2014;73:1071-8. doi: 10.1136/annrheumdis-2012-202818
  13. De Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73:1331-9. doi: 10.1136/annrheumdis-2013-204788
  14. Duran J, Bockorny M, Dalasl D, et al. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systemic review. Ann Rheum Dis. 2016;75:1595-8. doi: 10.1136/annrheumdis-2016-209383
  15. Green M, Marzo-Ortega H, Wakefield RJ, et al. Predictors of Outcome in Patients With Oligoarthritis Results of a Protocol of Intraarticular Corticosteroids to All Clinically Active Joints. Arthritis Rheum. 2001;44:1177-3. doi: 10.1002/1529-0131(200105)44:5<1177::AID-ANR201>3.0.CO; 2-5
  16. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34-45. https://www.ncbi.nlm.nih.gov/pubmed/ 16396980. doi: 10.1136/ard.2005.044354
  17. Сивордова Л.Е., Заводовский Б.В., Полякова Ю.В. и др. Доказательства целесообразности применения эторикоксиба в терапии остеоартроза у пациентов старших возрастных групп. Успехи геронтологии. 2016;29(2):286-90. Ссылка активна на 20.02.2020 [Sivordova LE, Zavodovskij BV, Poljakova YuV, et al. Evidence of the feasibility of using etorikoksib in the therapy of osteoarthritis in patients of older age groups. Uspekhi Gerontologii = Advanced Gerontology. 2016;29(2):286-90 (In Russ.)]. http://www.gersociety.ru/netcat_files/userfiles/10/AG_2016-29-02.pdf
  18. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857. doi: 10.1136/bmj.i4857
  19. Bhala N, Emberson J, Merhi A, et al. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9
  20. Заводовский Б.В., Сивордова Л.Е. Кардиоваскулярная безопасность применения нестероидных противовоспалительных препаратов при хронических воспалительных ревматических заболеваниях. Терапевтический архив. 2018;90(8):101-6 [Zavodovsky BV, Sivordova LE. Cardiovascular safety of the use of non-steroidal anti-inflammatory drugs for chronic inflammatory rheumatic diseases. Therapeutic Archive. 2018;90(8):101-6 (In Russ.)]. doi: 10.26442/terarkh2018908101-106
  21. Насонов Е.Л., Мазуров В.И., Лила А.М. и др. Резолюция Совещания Экспертов по теме: «Вопросы повышения доступности инновационных методов для пациентов со спондилоартритами». Научно-практическая ревматология. 2017;55(4):457-60 [Nasonov EL, Mazurov VI, Lila AM, et al. Resolution of the Meeting of Experts on the topic: «Issues of increasing the availability of innovative methods for patients with spondylitis». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):457-60 (In Russ.)]. doi: 10.14412/1995-4484-2017-457-459
  22. Arboleya LR, de la Figuera E, Soledad García M. Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs. Curr Med Res Opin. 2003;19(4):278-87. doi: 10.1185/030079903125001712
  23. Lemmel EM, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146-53. doi: 10.1185/030079902125000507
  24. Nikose S, Arora M, Singh P, et al. Hepatotoxicity and Changes in Liver Enzymes Due to Use of Non-Steroidal Anti Inflammatory Drugs (NSAIDs) in Non-Traumatic Musculoskeletal Painful Disorders. Molecular Enzymology and Drug Targets. 2015;1. doi: 10.21767/2572-5475.10007
  25. Инструкция по применению. Ссылка активна на 25.02.2020 [Instructions for use (In Russ.)]. https://vertex.spb.ru/products/prescription- medicines/alental/
  26. Pareek A, Chandanwale AS, Oak J, et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac – an Indian experience. Curr Med Res Opin. 2006;22(5):977-88. doi: 10.1185/030079906X104722
  27. Pareek A, Chandurkar N. Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Curr Med Res Opin. 2013;29:849-59. doi: 10.1185/03007995.2013.795139
  28. Perez Busquier M, Calero E, Rodriguez M, et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol. 1997;16:154-9. doi: 10.1007/bf02247844
  29. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-46. doi: 10.2165/11633470-000000000-00000
  30. Batlle-Gualda E, Ivorra JR, Mola EM, et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double blind 6 week randomized controlled trial. Osteoarthritis Cartilage. 2007;15:900-8. doi: 10.1016/j.joca.2007.02.008
  31. Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В. и др. Сравнительная эффективность и безопасность эторикоксиба и мелоксикама в лечении больных гонартрозом. Терапевтический архив. 2016;88(12):78-81 [Zavodovskij BV, Sivordova LE, Poljakova YuV, et al. Comparative efficacy and safety of etorikoksib and meloxicam in the treatment of patients with gonarthrosis. Therapeutic Archive. 2016; 88(12):78-81 (In Russ.)]. doi: 10.17116/terarkh2016881278-81
  32. Каратеев А.Е. Ацеклофенак в ревматологии: «золотая середина». Современная ревматология. 2013;7(2) [Karateev AE. Aceclofenac in rheumatology: the «golden mean». Sovremennaja revmatologija = Modern rheumatology. 2013;7(2):88-94 (In Russ.)]. doi: 10.14412/1996-7012-2013-2389
  33. Каратеев А.Е., Денисов Л.Н., Маркелова Е.И. и др. Результаты клинического исследования АЭРОПЛАН (анализ эффективности и риска осложнений при лечении артрита ацеклофенаком и нимесулидом). Consilium Medicum. 2013;15(2):52-7 [Karateev AE, Denisov LN, Markelova EI, et al. Rezul’taty klinicheskogo issledovanija AJeROPLAN (analiz jeffektivnosti i riska oslozhnenij pri lechenii artrita aceklofenakom i nimesulidom). Consilium Medicum. 2013;15(2):52-7 (In Russ.)]. https://www.elibrary.ru/item.asp?id=19671275&
  34. Martin-Mola E, Gijon-Banos J, Ansoleaga J. Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Rheum Int. 1995;15(3):111-6. doi: 10.1007/bf00302127
  35. Каратеев А.Е., Погожева Е.Ю., Филатова Е.С. и др. Факторы, влияющие на результаты анальгетической терапии. Результаты российского многоцентрового исследования НОТА (НПВП для Обезболивания: Терапевтический Анализ). Терапевтический архив. 2018;90(6):65-73. [Karateev AE, Pogozheva EJu, Filatova ES, et al. Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy. Therapeutic Archive. 2018; 90(6):65-73 (In Russ.)]. doi: 10.26442/terarkh201890665-73

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 123

PDF (Russian) - 29

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies